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Abstract 
Recent findings in colon cancer cells indicate that inhibition of the mitochondrial 
H+-ATP synthase by the ATPase Inhibitory Factor 1 (IF1) promotes aerobic glycolysis 
and a ROS-mediated signal that enhances proliferation and cell survival. Herein, we 
have studied the expression, biological relevance, mechanism of regulation and 
potential clinical impact of IF1 in some prevalent human carcinomas. We show that IF1 
is highly overexpressed in most (> 90 %) of the colon (n=64), lung (n=30), breast 
(n=129) and ovarian (n=10) carcinomas studied as assessed by different approaches in 
independent cohorts of cancer patients. The expression of IF1 in the corresponding 
normal tissues is negligible. By contrast, endometrium, stomach and kidney show high 
expression of IF1 in the normal tissue revealing subtle differences by carcinogenesis. 
The overexpression of IF1 also promotes the activation of aerobic glycolysis and a 
concurrent ROS signal in mitochondria of lung, breast and ovarian cancer cells 
mimicking the activity of oligomycin. IF1-mediated ROS signaling activates cell-type 
specific adaptive responses aimed at preventing death in these cell lines. Remarkably, 
regulation of IF1 expression in colon, lung, breast and ovarian carcinomas is exerted at 
post-transcriptional levels. We demonstrate that IF1 is a short-lived protein (t1/2 ~100 
min) strongly implicating translation and/or protein stabilization as main drivers of 
metabolic reprogramming and cell survival in these human cancers. Analysis of tumor 
expression of IF1 in cohorts of breast and colon cancer patients revealed its relevance as 
a predictive marker for clinical outcome, emphasizing the high potential of IF1 as 
therapeutic target. 
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Introduction 
Down-regulation of oxidative phosphorylation and concurrent activation of 
aerobic glycolysis is a hallmark feature of proliferating cells and of many different 
human carcinomas (1-3). An enhanced aerobic glycolysis provides the metabolic 
intermediates required to sustain proliferation (1,4). Several genetically-driven 
mechanisms directly promoting glycolysis, the inhibition of mitochondrial function or 
both have been proposed in order to explain energy metabolism in cancer cells and 
tumors (for review see (1,5)). Moreover, it has been suggested that the APC/C–Cdh1 
complex that controls the levels of PFKFB3 and hence, the rate of glucose consumption 
might participate in sustaining glycolysis in some types of human carcinomas (6). 
However, epigenetic mechanisms (7,8) and the tumor microenvironment (5,9) also play 
relevant roles in cancer development and progression by regulating the bioenergetic 
phenotype of cancer cells (10). 
The H+-ATP synthase is a master regulator of energy metabolism and cell fate. It 
is the mitochondrial protein complex of oxidative phosphorylation that catalyzes the 
synthesis of ATP using as driving force the proton gradient generated by the respiratory 
chain (11). The H+-ATP synthase is also required for efficient execution of cell death 
(12,13). In fact, cells that are unable to perform oxidative phosphorylation have an 
apoptotic-resistant phenotype (13-15). Conversely, activation of the bioenergetic 
function of mitochondria prevents tumor development (16,17).  
A compromised bioenergetic activity of mitochondria, as assessed by genomic 
(18), transcriptomic (10), proteomic (1,19) and functional studies (20), is involved in 
tumor progression and in chemotherapeutic resistance (21-24). Specifically, it has been 
described: (i) the down-regulation of the cellular abundance of the mRNAs that encode 
rate-limiting subunits of the H+-ATP synthase by either promoter hypermethylation of 
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the ATP5B gene (23) or by genetic deletion of ATP5A1 (18); (ii) the masking of the 
translation of β-F1-ATPase mRNA (25,26) through the binding of repressor proteins 
(27) that impede ribosome recruitment and translation and (iii) the over-expression in 
cancer cells and tumors of the ATPase Inhibitory factor 1 (IF1) that inhibits the activity 
of the mitochondrial H+-ATP synthase (28). Furthermore, recent findings indicate that 
IF1 has additional functions in colon cancer cells by promoting a ROS-mediated 
adaptive cellular response that triggers proliferation and resistance to cell death (29).  
In this investigation we have addressed (i) the study of the expression level of 
IF1 in different prevalent human carcinomas, (ii) the metabolic and signaling events that 
mediate IF1 overexpression in lung, breast and ovarian cancer cells, (iii) the 
mechanisms that mediate IF1 over-expression in tumors and (iv) its relevance as a 
prognostic marker in breast and colon cancer patients. Overall, the results indicate that 
IF1 has a very short half-life being highly overexpressed in colon, lung, breast and 
ovarian carcinomas by mechanisms that are regulated at post-transcriptional levels. In 
contrast, normal tissues that overexpress IF1, such as endometrium and kidney, reveal 
no relevant changes in IF1 triggered by carcinogenesis. The overexpression of IF1 
promotes the activation of aerobic glycolysis and concurrently confers a ROS-mediated 
resistance to staurosporine-induced cell death to lung, breast and ovarian cancer cells. 
Moreover, the tumor expression of IF1 is a predictive marker for clinical outcome in 
breast and colon cancer patients. Because IF1 masters the reprogramming of energy 
metabolism and signals cell-death resistance in cancer cells, we suggest that IF1 offers a 
relevant molecule with high potential as a new therapeutic target for treatment of 
prevalent human carcinomas.  
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Results 
 IF1 is over-expressed in most prevalent human carcinomas. Western blots in 
Figure 1 illustrate that the monoclonal antibody (28) recognizes the recombinant as well 
as the two major isoforms (~12 and ~8 kDa) of native IF1 in normal human liver and 
stomach extracts (Fig. 1). The expression of IF1 is negligible in normal breast, colon 
and lung (Fig. 1) but sharply increases in their corresponding carcinomas (Fig. 1). 
Colon carcinomas also express the short ~8 kDa IF1 isoform (Fig. 1). Interestingly, 
normal stomach shows a high expression of IF1 and revealed no relevant changes by 
carcinogenesis (Fig. 1). It should be noted that heart (not shown) and liver (Fig. 1) are 
the normal human tissues with highest expression of IF1.  
The expression of IF1 was also assessed by immunohistochemistry in a different 
cohort of normal human tissues and carcinomas (Fig. 2). Consistent with western blot 
data (Fig. 1), immunohistochemistry of cancer tissue microarrays confirmed that the 
expression of IF1 is negligible in normal colon, lung, breast and ovary (Fig. 2). In 
contrast, carcinomas in these tissues showed a highly significant increase in the granular 
cytoplasmic immunostaining of IF1 (Fig. 2). Contrary to these findings the expression 
of IF1 in normal epithelial cells of the endometrium and kidney was very high (Fig. 2) 
and its content did not show significant changes by carcinogenesis (Fig. 2).  
Post-transcriptional regulation of IF1 expression in cancer. Details on the 
analysis of the promoter region of the human IF1 gene (ATPIF1) and its possible 
relationship with the expression of HIF-1α (30) are provided in Supplemental Fig. S1 
and Fig. S2, respectively. In any case, the cellular availability of IF1 mRNA was not 
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significantly different in colon, lung and breast carcinomas when compared to that in 
the corresponding normal tissues (Fig. 3A). Moreover, IF1 mRNA was significantly 
reduced in ovarian carcinomas (Fig. 3A). 
The Immediate Early Response gene (IER3) has been shown to target IF1 for 
degradation by a mitochondrial protease (31). Studies aimed at characterizing the 
relevance of protein stability in the expression of IF1 in colon cancer cells revealed a 
very rapid accumulation of the protein in response to the serine-protease inhibitor 
AEBSF (Fig. 3B), suggesting the participation of either the ATP-dependent Lon 
protease or ClpXP (32) in the degradation of IF1. The short half-life of IF1 was further 
demonstrated by pulse-chase experiments (Fig. 3C) that indicated a t1/2 for the protein 
of ~ 100 min. Overall, these findings indicate the relevance of translational and post-
translational regulatory mechanisms for the expression of IF1 in cancer.  
Analysis of the expression of IER3 in lung, breast and colon carcinomas 
revealed that it is overexpressed in 16 out of the 18 carcinomas analyzed (Supplemental 
Fig. S3A). Moreover, partial silencing of the protein in colon cancer cells revealed no 
relevant effect on the expression of IF1 (Supplemental Fig. S3B), what suggests that 
degradation of IF1 is a complex process.  
 IF1 regulates energy metabolism in lung, breast and ovarian cancer cells. 
Consistent with previous reports in colon cancer cells (29), the overexpression of IF1 in 
lung, breast and ovarian cancer cells promoted a significant increase in the rates of 
aerobic glycolysis (Fig. 4A). The increase in glycolysis was similar to that exerted by 
incubation of the cells with oligomycin, a pharmacological inhibitor of the H+-ATP 
synthase (Fig. 4A). Conversely, siRNA-mediated silencing of IF1 promoted a 
significant reduction in the rates of glycolysis in most cancer cells except in HOP62 
(Fig. 4A). The expression of IF1 varies largely between cancer cells (Fig. 4B) whereas 
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the basal rates of aerobic glycolysis were found to be quite similar (Fig. 4A), indicating 
that glycolysis is regulated by other factors in addition to the expression level of IF1 
(33).  
 IF1 overexpression generates a mitochondrial ROS signal in lung, breast 
and ovarian cancer cells. The overexpression of IF1 in lung, breast and ovarian cancer 
cells promoted a significant increase in the production of superoxide radical (Fig. 5). 
The mitochondrial scavenger MitoQ (MQ) (34) was able to quench the production of 
superoxide in all cell lines studied (Fig. 5), supporting the role of IF1 as a general ROS-
mediating signaling molecule in mitochondria (29). We should mention that the IF1-
mediated ROS signal generated in mitochondria is of mild intensity because neither the 
cellular hydrogen peroxide levels nor the GSH/GSSG ratio have been found to be 
altered by IF1 overexpression (29). 
 In sharp contrast with the findings in colon cancer cells (29) the IF1-mediated 
ROS signal was unable to stimulate cellular proliferation as assessed by the 
incorporation of EdU into cellular DNA in lung, breast and ovarian cancer cells 
(Supplemental Fig. S4).  
 Mitochondrial ROS protect lung, breast and ovarian carcinomas from 
staurosporine (STS)-induced cell death. The IF1-mediated ROS signal was able to 
protect lung, breast and ovarian cancer cells from STS-induced cell death (Fig. 6). 
Quenching the ROS signal with MQ prevented protection against STS-induced cell 
death (Fig. 6). Interestingly, we observed that the intensity of the ROS-mediated 
response to IF1 overexpression (Fig. 5) correlated with the degree of protection against 
STS-induced cell death (plot in Fig. 6) suggesting a relevant role for mitochondrial ROS 
signaling in promoting survival pathways in all cancer cells.  
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For instance, and in support of this idea, transcriptional activity of the NFκB 
promoter in lung, breast and ovarian carcinomas was greatly enhanced by IF1 
overexpression (Fig. 7A) and partially quenched by the mitochondrial ROS scavenger 
MQ (Fig. 7A). The ROS-mediated activation of the NFκB pathway in HOP62 lung 
cancer cells is supported by a reduction in the expression of the NFκB repressor IκBα 
and the concurrent increase in the expression of the anti-apoptotic Bcl-xL (Fig. 7B). 
These changes were partially reversed by the mitochondrial ROS scavenger MQ (Fig. 
7B). However, the same studies in breast (BT549, HS578T) and ovarian (OVCAR 8) 
cancer cells did not provided similar findings (data not shown) emphasizing the 
complexity of the survival pathways that are activated in cancer cells in response to 
mitochondrial ROS signaling.  
Clinical relevance of IF1 in breast cancer. A next question was to assess the 
potential relevance of IF1 in the clinics. We determine the expression level of IF1 in a 
cohort of tumors of breast cancer patients operated from invasive carcinomas for which 
the bioenergetic signature or BEC index (β-F1-ATPase/Hsp60/GAPDH ratio) and 
follow-up information is available (35,36). The results in Supplemental Table S1 
summarize the clinicopathological characteristics of the cohort of patients studied and 
the expression level of IF1 in the carcinomas according to the clinical information. It 
should be noted that the expression of IF1 in normal breast biopsies was negligible 
(Figs. 1&2). Although the tumor expression of IF1 did not show significant differences 
between patients with clinical-pathological markers relevant for tumor progression such 
as nodal involvement, tumor size and histological grade (Supplemental Table S1), it 
was significantly diminished in the poor prognosis groups of lobular and hormone 
receptor negative carcinomas when compared to ductal and hormone receptor positive 
carcinomas, respectively (Supplemental Table S1).  
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From the molecular point of view the expression of IF1 inversely correlated with 
the BEC-index (35) of the tumors (R= -0.437; P=0.0001), suggesting that the increased 
expression of IF1 parallels the program of repression of the bioenergetic activity of 
mitochondria in cancer cells. Surprisingly, Kaplan-Meier survival analysis revealed that 
a low tumor expression of IF1 predicted a higher rate for disease-recurrence in breast 
cancer patients (Fig. 8A).  
Clinical relevance of IF1 in colon cancer. Next, we determine the quantity of 
IF1 in normal and tumor biopsies in a cohort of colon cancer patients in which the 
markers of energy metabolism have been previously quantified (37). The amount of IF1 
was determined using reverse phase protein microarrays (Supplemental Fig. S5) (37). 
The results in Supplemental Table S2 summarize the clinicopathological characteristics 
of the cohort of patients studied and the quantity of IF1 in the carcinomas according to 
the clinical information. Colon carcinomas showed a significant two-fold increase in the 
amount of IF1 when compared to normal colon biopsies (Supplemental Table S2). The 
tumor content of IF1 did not show significant differences between patients with clinical-
pathological markers relevant for tumor progression (Supplemental Table S2).  
In colon cancer the expression of IF1 also inversely correlated with the BEC-
index (37) of the tumors (R= -0.526; P=0.001), once again suggesting that the increased 
expression of IF1 in colon cancer cells parallels the program of metabolic 
reprogramming experienced by these carcinomas. Kaplan-Meier survival analysis also 
revealed that a low tumor expression of IF1 predicted a worst overall prognosis for 
colon cancer patients (Fig. 8B).  
 10
Discussion 
 We show that IF1 is highly overexpressed in all human carcinomas of the colon, 
lung, breast and ovary showing negligible expression in their corresponding normal 
tissues. IF1 promotes the activation of aerobic glycolysis and generates a concurrent 
ROS signal in mitochondria that activates cell-type specific adaptive responses aimed at 
preventing death in lung, breast and ovarian cancer cells. Mechanistically, IF1 mimics 
the effects of oligomycin, an inhibitor of the H+-ATP synthase (13,29). Remarkably, we 
show that the regulation of the expression of IF1 in carcinomas of the colon, lung, 
breast and ovary is exerted at post-transcriptional levels. In fact, we demonstrate that 
IF1 is a short-lived protein that is degraded by mitochondrial serine-proteases. Overall, 
we provide the first demonstration supporting that regulation of the synthesis and/or 
degradation of a mitochondrial protein involved in the control of oxidative 
phosphorylation plays a master role in metabolic rewiring and in signaling cell-death 
resistance in prevalent human carcinomas. Moreover, we show that IF1 expression has 
relevance as a predictive marker for clinical outcome in breast and colon cancer 
patients. 
 The expression level of IF1 varies greatly within normal human tissues. 
Consistent with the role of IF1 as inhibitor of the H+-ATP synthase (28,29) a high 
expression of IF1 in normal tissues such as heart, liver and kidney would imply the 
partial mass-action mediated inhibition of oxidative phosphorylation and thus a 
limitation in cellular ATP availability. This situation is obviously not possible because 
these tissues have a very high metabolic demand. Thus, our findings suggest that in 
addition to the well characterized pH regulated binding of IF1 to the H+-ATP synthase 
(38) a mechanism should exist in tissues with high metabolic demand to promote the 
mass-action mediated inhibition of IF1 on the H+-ATP synthase activity (28). In this 
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regard, it has been described that IF1 also binds other membrane proteins of 
mitochondria in a pH and ΔΨm independent manner (39,40) hampering its activity as an 
inhibitor of the ATPase (40). Alternatively, potential tissue-specific post-translational 
modifications of IF1 could explain the differential activity exerted by IF1 in different 
human tissues. 
 At variance with other mitochondrial proteins (41) we show that IF1 is a short-
lived protein with a turnover in the range of minutes. This finding is of utmost 
importance to understand the bioenergetic activity of mitochondria. In fact, a rapid 
turnover of the protein would allow cells to quickly adapt the output of ATP by 
oxidative phosphorylation to changing physiological cues. One can speculate that 
mutations in cancer genes or other epigenetic events of the tumor microenvironment 
switch-on the mechanisms that promote a high expression of IF1 in the tumor. We 
suggest that an increase in translation of IF1 mRNA and/or in the stability of the protein 
should occur in human carcinomas to provoke the overwhelming expression of IF1 
observed in these tumors. The control of IF1 translation is presently unknown and it 
might involve regulatory proteins and miRNAs as we have shown for β-F1-ATPase 
mRNA (27,42,43).  
IER3 gene has been shown to suppress ROS production and to render IF1 prone 
to proteolytic digestion (31). Paradoxically, and in contrast with findings in ovarian (44) 
and pancreatic (45) cancer our results indicate that IER3 is overexpressed in lung, breast 
and colon cancer. Moreover, we found no correlation between IER3 and IF1 expression 
suggesting that the control of the degradation of IF1 is more complex than originally 
anticipated and that the participation of IER3 might depend on the cell type analyzed. 
An alternative explanation for the accumulation of IF1 in carcinomas could be the 
partial inactivation of the mitochondrial serine-protease involved in its turnover. In this 
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regard, the Lon protease has been reported to diminish its activity during ageing (46). 
Moreover, cancer cells exhibit high basal levels of oxidative stress (5) and the Lon 
protease is particularly vulnerable to inactivation by ROS (47). The implication of 
ClpXP in human pathology is scant despite its relevance in the degradation of proteins 
involved in metabolic reprogramming (48). As previously discussed, potential 
oncogene- and/or metabolic-driven post-translational modifications of IF1 could also 
explain its accumulation in carcinomas if such changes hamper the mitochondrial 
pathway of IF1-degradation.  
Despite the large structural and molecular differences of mitochondria in 
mammalian cells (49), but consistent with previous findings in colon cancer (29), we 
show that the IF1-mediated inhibition of the H+-ATP synthase switches on aerobic 
glycolysis and generates a mitochondrial ROS signal in all cancer cells studied. 
Mitochondrial ROS signaling represents a pathway of retrograde communication to the 
nucleus of the cell that influences adaptive cellular responses (50). The results herein 
indicate that whereas mitochondrial ROS signaling triggers protection against cell death 
in all cellular types studied it is unable to stimulate proliferation in lung, breast and 
ovarian carcinomas, what is at variance with colon cancer cells (29). These findings 
indicate the existence of common as well as cell-type specific programs of nuclear 
response to mitochondrial ROS signaling. The effect of ROS on the cellular response 
depends on the level (51) and site (52) at which are being produced. Moreover, ROS 
interact with diverse signaling pathways being transcription factor NFκB a crucial 
regulator of adaptive responses related with survival (53,54). In colon cancer cells IF1 
mediated the activation of the canonical NFκB pathway of survival (29). The results 
herein support that although IF1 is able to trigger the ROS-mediated transcriptional 
activation of the NFκB promoter as a common response to lung, breast and ovarian 
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cancer cells, only lung carcinomas seem to activate the same NFκB-mediated survival 
pathway. These results emphasize the critical function that NFκB plays in signaling 
lung tumor development, in agreement with previous findings in a mouse model of lung 
carcinogenesis (55), and highlight the need of specific studies aimed at unveiling the 
IF1-mediated pathways of survival that are activated in breast and ovarian cancer cells.   
Redox regulation has an essential role in malignancies (29,56,57) but the 
mechanisms of its actions and its impact in tumor prognosis remain unclear. Contrary to 
what would be expected for an oncogenic protein (58), we found that breast and colon 
cancer patients with high tumor expression of IF1 have a better prognosis. There are 
other examples in the literature illustrating similar paradoxes. For instance, miR-200s 
that modulate the oxidative stress response increase tumor growth in mouse models 
(59). However, a high-expression of miR-200s is linked to a favorable prognosis (60) 
whereas downregulation of miR-200s is associated with relapse in patients with ovarian 
cancer (61). Similarly, IDH mutations are paradoxically associated with better survival 
in glioma patients (62). Because a low expression of IF1 in carcinomas predicts a 
shorter time for relapse or death of the patient, we suggest that cells with low expression 
of IF1 are more likely to metastasize. In this regard, it is possible that cells with high 
expression of IF1 which have a low bioenergetic signature become more vulnerable to 
metabolic or other forms of stress during detachment and/or become more easily 
recognized by the immune system (2). Indeed, cells with a low bioenergetic signature 
are addicted to glucose and are more sensitive to glucose deprivation and the inhibition 
of glycolysis (24,63). 
Overall, we document that the short-lived inhibitor of the mitochondrial H+-ATP 
synthase is overexpressed in colon, lung, breast and ovarian cancer mastering the 
reprogramming of energy metabolism and signaling a cell-death resistance phenotype. 
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Moreover, we support its potential as a marker of clinical outcome in breast and colon 
cancer patients. We stress that specific studies and animals models are needed to unveil 
the molecular and cellular biology of IF1 in the different cell types of mammals.  
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Materials and Methods 
Patient specimens and protein extraction. Frozen tissue obtained from 
surgical specimens of untreated cancer patients with primary adenocarcinomas of the 
breast, colon, stomach, kidney and lung were obtained from the Banco de Tejidos y 
Tumores, IDIBAPS (Instituto de Investigaciones Biomédicas Pi y Suñer), Hospital 
Clinic, Barcelona, Spain (64). A collection of frozen tissue sections obtained from 
surgical specimens of (i) ninety-three patients who had an operation for invasive breast 
carcinoma at the Hospital Universitario La Paz between 1991 and 2000 (35,36) and (ii) 
of untreated cancer patients with primary colorectal adenocarcinomas (CRC) enrolled in 
the incident Spanish CRC Epicolon Study and prospectively followed during 5 years 
(37,65) obtained from the Banco de Tejidos y Tumores, Hospital Meixoeiro, Vigo, 
Spain were also used (see Supplementary Information for Bioethic details).  
Cell cultures, treatments, transfections and siRNA silencing. Human cervical 
(HeLa), breast (HS578T, NCI-ADR-RES, BT549, MCF12), lung (A549, HOP62), 
colon (KM12, HCT116) and ovarian (OVCAR 8, OVCAR 3) cells were grown 
following the suppliers´ instructions. When needed, cells were left untreated or treated 
with 200 μM CoCl2 (Sigma) for 6h. For inhibition of mitochondrial serine-proteases 
HCT116 cells were treated with 400 μM of 4-(2-aminoethyl) benzenosulfonyl fluoride 
hydrochloride (AEBSF) for the indicated time. Transfection and silencing experiments 
were performed as recently described (29).  
Protein fractionation and Western blots. Cell lysis and protein fractionation 
were carried out as described (27). The primary antibodies used were: anti-β-actin 
(Sigma, 1:20000), anti-β-F1-ATPase ((66), 1:20000), anti-IkBα and anti-Bcl-xL (Cell 
Signaling, 1:1000), anti-HIF-1α (Santa Cruz Biotechnology, 1:150) and anti-IF1 ((28), 
1:200).  
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Immunohistochemistry. Cancer Survey Tissue Microarrays (TMA, OriGene) 
containing 5 μm sections of formalin-fixed normal and tumor specimens of breast, 
colon, lung, kidney, ovarian and endometrial tissues were immunostained using the 
monoclonal anti-IF1 (1:200) antibody as previously described (19). Sections were 
counterstained with hematoxylin.  
Quantification of mRNA expression. Human β-F1-ATPase and IF1 mRNA 
levels in normal and tumor tissues were carried out by qPCR using breast (BCRT101), 
ovarian (HORT102), colon (HCRT103) and lung (HLRT104) TissueScan Tissue qPCR 
Arrays from OriGene Technologies, Inc (Rockville, MD). For detailed pathological 
information of these patients see Supplemental Table S3. Real time qPCR was 
performed as described (27). The following forward (F) and reverse (R) primers were 
used to amplify human β-F1-ATPase and IF1 cDNAs: F: 5`- cagcagattttggcaggtg-3’, R: 
5´-cttcaatgggtcccaccata-3’; F: 5’-gggccttcggaaagagag-3’ and R: 5’-ttcaaagctgccagttgttc-
3’, respectively.  
Metabolic labeling and immunoprecipitation. Metabolic labeling was initiated 
by addition to the culture medium 0.65 mCi of [35S]-methionine/ml. Duration of the 
pulse was 1h. At the indicated time-points IF1 was immunoprecipitated from cellular 
lysates using G-sepharose pre-coated with 12 μg of anti-IF1 IgGs (67).  
Quantification of IF1 in CRC biopsies using reverse phase protein 
microarrays. IF1 was expressed and purified as detailed (28). Samples from CRC 
patients were diluted in PBS to a final protein concentration of 1 μg/μl before printing 
onto nitrocellulose-coated glass slides (FAST Slides, Scheleicher & Schuell BioScience, 
Inc.) using a BioOdyssey Calligrapher MiniArrayer printer (Bio-Rad Laboratories, Inc.) 
as recently described (37). Arrays were incubated with anti-IF1 (1 μg/ml) followed by 
incubation with a donkey anti-mouse conjugated with alexa-488 (Invitrogen). 
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Microarrays were scanned using a Typhoon 9410 scanner (GE Healthcare, Inc.). The 
mean fluorescent intensity of the spots was quantified using Image J software (N.I.H., 
USA) and converted into pg of protein/ng of total protein using the fluorescent intensity 
units obtained in the respective standard curve of recombinant protein (37).  
Bioinformatic Search of the ATPIF1 Gene: UCSC Genome Browser 
(http://genome.ucsc.edu/) was used. Chip-sep data was obtained from ENCODE 
database.  
Determination of reactive oxygen species. Where indicated, approximately 2 x 
105 cells were incubated overnight with 10-20 nM of MQ. The intracellular production 
of superoxide radical was monitored by flow cytometry using 5 μM MitoSOX™ 
(Invitrogen) incubated 15 min at 37º C (29). Cells were analyzed in a FACScan. For 
each analysis 10,000 events were recorded. 
Other methods. Details for the determination of aerobic glycolysis, 
proliferation, cell death and NFκB promoter activity have been recently provided (29). 
Where indicated 5 nM of MQ was added to the incubation. 
Statistical analysis. Distribution of molecular markers and other categorical 
variables were compared by χ2 and Student’s t-test. The statistical significance of linear 
regressions was assessed by Pearson’s correlation t-test. To determine the association 
between the expression level of IF1 with disease-free survival (DFS) and overall 
survival (OS) the cutoff point used to define high and low risk groups was the mean 
value of protein expression in normal breast or colon samples. Survival curves were 
derived from Kaplan-Meier estimates and compared by log-rank test. Statistical test 
were two-side at the 5% level of significance. All computations were carried out using 
SPSS, version 17.0. 
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Legend to Figures. 
Figure 1. Expression of human IF1 in normal and tumor tissues. Western blots 
reveal the expression of IF1 (h-IF1) in SDS-PAGE fractionated proteins from normal 
(N) and tumor (T) biopsies of different human tissues. The antibody recognizes the 
recombinant protein (RP) as well as the two major 12- and 8-kDa protein isoforms of 
IF1. β-actin expression is shown as loading control. For comparison purposes, the 
expression level of IF1 in human tissues (histograms) is normalized relative to its 
expression in HeLa cells (a.u.) assayed in the same blot. The number of paired normal 
and tumor biopsies analyzed is indicated in parenthesis.   
Figure 2. IF1 is upregulated in some prevalent human carcinomas. Representative 
immunohistochemistries of IF1 expression in normal and tumor tissue of colon, lung, 
breast, ovary, endometrium and kidney. Magnification 20x, 40x and 63x. Histograms to 
the right of the pictures show the quantification of IF1 expression in normal (N, green, 
n=5) and tumor (T, red, n=10) specimens expressed as arbitrary units (a.u.). The results 
shown are the mean±S.E.M. *, P<0.05 when compared to normal by Student’s t test. 
Note that whereas normal epithelial cells from the colon, lung, breast and ovary show 
low or negligible expression of IF1, endometrial and kidney cells have very high 
expression of IF1.  
Figure 3. IF1 expression is regulated at post-transcriptional levels. A, Colon 
(HCRT103), lung (HLRT104), breast (BCRT101) and ovarian (HORT102) TissueScan 
Tissue qPCR Arrays were used to determine the expression of IF1 mRNA in different 
normal (open bars) and tumor (closed bars) tissue specimens. The number of studied 
patients is indicated in brackets. The results shown are the mean±S.E.M. *, P<0.001 
when compared to normal by Student’s t test. B, HCT116 cells were treated with 400 
μM of the serine-proteases inhibitor AEBSF for the indicated time and the expression of 
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IF1 and β-actin (loading control) analyzed by western blot. Lanes 1 and 2, show 
different experiments of the same condition. Bars are the mean ± S.E.M. of four 
experiments. *, P<0.05 when compared to 0h by Student’s t test. C, After metabolic 
labeling with 35S-methionine IF1 was immunoprecipitated from HCT116 cells at the 
indicated time. Lanes 1 and 2, show different experiments of the same condition of the 
chase. The fluorogram reveals the migration of both the precursor and mature IF1 
(arrow) 35S-labeled immunoprecipitated proteins. The plot shows the first order rate 
kinetics of the decay of IF1. The t1/2 for IF1 is in the 105-120 min range.  
 
Figure 4. IF1 regulates the activity of aerobic glycolysis in lung (HOP62, A549), 
breast (BT549, HS578T) and ovarian (OVCAR8, OVCAR3) cancer cells. A, Cells 
transfected with CDL-GFP-β-3’UTR were co-transfected with control (CRL and siCRL, 
open bars), IF1 plasmid (IF1+, dark grey bars) or siIF1 siRNA (siIF1, light grey bars) to 
regulate the expression of IF1 for the determination of the rates of aerobic glycolysis. 
The effect of 6 μM oligomycin (OL, closed bars) is shown. Representative blots of IF1 
and β-F1-ATPase (β-F1) expression. Bars are the mean±S.E.M. of six different samples. 
*, P<0.05 when compared to CRL by Student’s t test. B, IF1 (h-IF1) expression in 20 μg 
of protein from different human cell lines. Two different exposures of the IF1 film are 
presented. β-actin expression is shown as loading control.  
 
Figure 5. IF1 regulates mitochondrial ROS production in lung (HOP62, A549), 
breast (BT549, HS578T) and ovarian (OVCAR8, OVCAR3) cancer cells. Cells 
transfected with CDL-GFP-β-3’UTR were co-transfected with control (CRL, open and 
light grey bars) or IF1 plasmid (IF1, dark grey and closed bars) in the absence or 
presence (+MQ) of 5 nM of the mitochondrial ROS scavenger MitoQ (MQ). The 
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superoxide radical was determined by FACS analysis using MitoSox. The data shown 
are mean±S.E.M. of twelve different samples. *, P<0.05 and #, P<0.05 when compared 
to CRL or IF1 by Student’s t test, respectively.  
 
Figure 6. IF1 regulates the cell death response in lung (HOP62, A549), breast 
(BT549, HS578T) and ovarian (OVCAR8) cancer cells. Cells transfected with CDL-
GFP-β-3’UTR were co-transfected with control (CRL, open and light grey bars) or IF1 
plasmid (IF1, dark grey and closed bars) in the absence or presence (+MQ) of 5 nM of 
the mitochondrial ROS scavenger MitoQ (MQ). 24h after transfection the cells were 
treated with 1 μM staurosporine (STS) and 24h later the cells were stained with 
propidium iodide and the green population of cells was analyzed by flow cytometry to 
evaluate the percentage of sub-G0 cells. The data shown are mean±S.E.M. of six-nine 
different samples. *, P<0.05 and #, P<0.05 when compared to CRL or IF1 by Student’s 
t test, respectively. The plot shows the linear correlation that exists between the IF1-
mediated ROS-response and the observed cell death.  
 
Figure 7. IF1 triggers transcriptional activation of the NFκB promoter in lung 
(HOP62), breast (BT549) and ovarian (OVCAR8) cancer cells. Cells transfected 
with CDL-GFP-β-3’UTR were co-transfected with control (CRL, open and light grey 
bars) or IF1 (IF1, dark grey or closed bars) plasmid in the absence or presence (+MQ) 
of 5 nM of the mitochondrial ROS scavenger MitoQ (MQ). A, A luciferase reporter 
plasmid of the NKκB promoter was cotransfected and the luciferase activity was 
determined in cellular extracts after 24-h transfection. The data shown are mean±S.E.M. 
of ten samples. *, P<0.05 and #, P<0.05 when compared to CRL or IF1 by Student’s t 
test, respectively. B, Cellular proteins of HOP62 were fractionated on SDS-PAGE and 
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processed for western blotting with the indicated primary antibodies. Representative 
blots are shown. The results are mean±S.E.M. of three experiments. *, P<0.05 and  #, 
P<0.05 when compared to CRL or IF1 by Student’s t test, respectively. 
 
Figure 8. Kaplan-Meier survival analyses reveal the clinical relevance of IF1. A, 
Protein samples from breast tumor biopsies were analyzed by western blot for the 
expression level of IF1. Kaplan-Meier disease-free survival (DFS) analysis for 93 breast 
cancer patients stratified by the tumor expression level of IF1. The plot shows a 
significant association of low IF1 expression with a poor outcome for the patients. The 
log-rank test p-value is shown. B, Protein samples from normal and tumor biopsies from 
a cohort of patients with colorectal cancer were analyzed by Reverse Phase Protein 
Microarrays to quantify IF1 (see Supplemental Fig. S4). Kaplan-Meier overall survival 
(OS) analysis for 38 colon cancer patients stratified by the tumor quantity of IF1. The 
plot shows a significant association of low IF1 expression with a poor outcome for the 
patients. The log-rank test p-value is shown. 
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